Hyperphosphatemia Clinical Trial
Official title:
Individualized Treatment of Hyperphosphatemia Based on Phosphate Balance in Maintenance Hemodialysis Patients: a Multicenter, Randomized Clinical Trial
The research is designed as a prospective, randomized, controlled clinical trial without blinding. A total of 116 participants with hyperphosphatemia will be enrolled from three hemodialysis center (56 from Huashan Hospital, 30 from Huadong Hospital and 30 from Tongji Hospital). All participants will be randomly divided into control group and intervention group in a ratio of 1:1. Phosphorus balance status is evaluated in participants of the intervention group by the phosphorus balance calculator. Then, these participants will be given individualized phosphate-binders, dietary and dialysis intervention according to the results of phosphorus balance evaluation. Participants in the control group will not receive the phosphorus balance status evaluation but receive phosphate-binder treatment according to the KDIGO Guidelines. Dietary phosphorus intake, dialysate calcium concentration and dose of active vitamin D, phosphorus-binders of all participants will be recorded during the whole research program. After two-week treatment, the phosphorus balance of participants in intervention group will be evaluated again and the therapeutic strategies then will be adjusted. At the same time, the therapeutic strategies of participants in the control group will be adjusted according to the serum phosphorus concentration. All participants will be followed up for two weeks again and receive blood test and related examinations at the end of study. The results of final examinations will be analyzed to evaluate the efficacy of individualized treatment of hyperphosphatemia.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
| Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
| Completed |
NCT01187628 -
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
|
Phase 3 | |
| Unknown status |
NCT01245517 -
The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient
|
N/A | |
| Completed |
NCT00506441 -
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
|
Phase 3 | |
| Recruiting |
NCT04440696 -
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
|
Phase 1/Phase 2 | |
| Completed |
NCT01976572 -
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01742585 -
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
|
Phase 3 | |
| Completed |
NCT01191255 -
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
|
Phase 3 | |
| Completed |
NCT01003223 -
Phosphate Kinetic Modeling
|
N/A | |
| Completed |
NCT00505037 -
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
|
Phase 2 | |
| Completed |
NCT00508885 -
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04551300 -
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
|
Phase 2 | |
| Completed |
NCT01955876 -
Fosrenol Post-marketing Surveillance in Japan
|
N/A | |
| Completed |
NCT04579315 -
Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease
|
N/A | |
| Terminated |
NCT01725113 -
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
|
Phase 4 | |
| Recruiting |
NCT01238588 -
The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
|
N/A | |
| Completed |
NCT00542815 -
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
|
Phase 3 | |
| Completed |
NCT04549597 -
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
|
Phase 4 | |
| Completed |
NCT04789876 -
Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia
|
N/A |